Cara Therapeutics reported $-27911000 in Operating Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Acadia Pharmaceuticals ACAD:US $ -113.02M 68.36M
Acelrx Pharmaceuticals ACRX:US $ -8995000 820K
Aerie Pharmaceuticals AERI:US $ -18.14M 15.51M
Cara Therapeutics CARA:US $ -27911000 5.61M
Chugai Pharma 4519:JP Y 99940M 87067M
Depomed DEPO:US $ 11.56M 3.58M
Endo International Ordinary Shares ENDP:US $ 68.99M 481.35M
Halozyme Therapeutics HALO:US $ 75.67M 19.14M
Horizon Pharma HZNP:US $ 88.56M 105.76M
Johnson & Johnson JNJ:US $ 5840M 22M
Neurocrine Biosciences NBIX:US $ -15.3M 18.4M
Pacira Pharmaceuticals PCRX:US $ 31.24M 13.84M
Pain Therapeutics PTIE:US $ -17821000 3.38M
Pfizer PFE:US $ 12102M 2229M
Redhill Biopharma RDHL:US $ -13.24M 7.46M
Revance Therapeutics RVNC:US $ -62221000 617K
Supernus Pharmaceuticals SUPN:US $ 11.35M 9.38M
Teva Pharmaceutical Industries TEVA:US $ -949M 236M
Vanda Pharmaceuticals VNDA:US $ 3.46M 11.13M